
Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity
Keywords: AES; botulism; botulinum neurotoxin; Human Botulism Immune Globulin; infant botulism; pentavalent botulinum toxoid; recombinant botulinum vaccine; AEs; adverse events; AUC; area under the plasma concentration-time curve; BIG-IV; Human Botulism Immune Globulin